138 related articles for article (PubMed ID: 29754637)
1. New Molecular Targets for Treatment of Cushing's Disease.
Foulkes E; Newell-Price J
Endocrinol Metab Clin North Am; 2018 Jun; 47(2):367-373. PubMed ID: 29754637
[TBL] [Abstract][Full Text] [Related]
2. USP8: a novel therapeutic target for Cushing's disease.
Jian F; Cao Y; Bian L; Sun Q
Endocrine; 2015 Nov; 50(2):292-6. PubMed ID: 26162929
[TBL] [Abstract][Full Text] [Related]
3. USP8 mutation in Cushing's disease.
Huang C; Shi Y; Zhao Y
Oncotarget; 2015 Jul; 6(21):18240-1. PubMed ID: 26285834
[No Abstract] [Full Text] [Related]
4. Recurrent gain-of-function USP8 mutations in Cushing's disease.
Ma ZY; Song ZJ; Chen JH; Wang YF; Li SQ; Zhou LF; Mao Y; Li YM; Hu RG; Zhang ZY; Ye HY; Shen M; Shou XF; Li ZQ; Peng H; Wang QZ; Zhou DZ; Qin XL; Ji J; Zheng J; Chen H; Wang Y; Geng DY; Tang WJ; Fu CW; Shi ZF; Zhang YC; Ye Z; He WQ; Zhang QL; Tang QS; Xie R; Shen JW; Wen ZJ; Zhou J; Wang T; Huang S; Qiu HJ; Qiao ND; Zhang Y; Pan L; Bao WM; Liu YC; Huang CX; Shi YY; Zhao Y
Cell Res; 2015 Mar; 25(3):306-17. PubMed ID: 25675982
[TBL] [Abstract][Full Text] [Related]
5. Biophysical and structural insight into the USP8/14-3-3 interaction.
Centorrino F; Ballone A; Wolter M; Ottmann C
FEBS Lett; 2018 Apr; 592(7):1211-1220. PubMed ID: 29473952
[TBL] [Abstract][Full Text] [Related]
6. Ubiquitin-specific protease 8 inhibitor suppresses adrenocorticotropic hormone production and corticotroph tumor cell proliferation.
Kageyama K; Asari Y; Sugimoto Y; Niioka K; Daimon M
Endocr J; 2020 Feb; 67(2):177-184. PubMed ID: 31666445
[TBL] [Abstract][Full Text] [Related]
7. Decoding the genetic basis of Cushing's disease: USP8 in the spotlight.
Theodoropoulou M; Reincke M; Fassnacht M; Komada M
Eur J Endocrinol; 2015 Oct; 173(4):M73-83. PubMed ID: 26012588
[TBL] [Abstract][Full Text] [Related]
8. Cushing's disease: current medical therapies and molecular insights guiding future therapies.
Lau D; Rutledge C; Aghi MK
Neurosurg Focus; 2015 Feb; 38(2):E11. PubMed ID: 25639313
[TBL] [Abstract][Full Text] [Related]
9. Clinical Spectrum of USP8 Pathogenic Variants in Cushing's Disease.
Rebollar-Vega RG; Zuarth-Vázquez JM; Hernández-Ramírez LC
Arch Med Res; 2023 Dec; 54(8):102899. PubMed ID: 37925320
[TBL] [Abstract][Full Text] [Related]
10. Cushing's disease: towards precision medicine.
Kaiser UB
Cell Res; 2015 Jun; 25(6):649-50. PubMed ID: 25930709
[TBL] [Abstract][Full Text] [Related]
11. Transcription Factor ASCL1 Acts as a Novel Potential Therapeutic Target for the Treatment of the Cushing's Disease.
Chen Z; Jia Q; Zhao Z; Zhang Q; Chen Y; Qiao N; Ye Z; Ji C; Zhang Y; He W; Shi C; Cai Y; Yao B; Han R; Wang Y; Shou X; Shen M; Cao X; Zhou X; Cheng H; Zhu J; Hu Y; Zhang Z; Ye H; Li Y; Li S; Wang Y; Ma Z; Ni T; Zhao Y
J Clin Endocrinol Metab; 2022 Jul; 107(8):2296-2306. PubMed ID: 35521682
[TBL] [Abstract][Full Text] [Related]
12. Genetics of Cushing's disease: an update.
Perez-Rivas LG; Reincke M
J Endocrinol Invest; 2016 Jan; 39(1):29-35. PubMed ID: 26208471
[TBL] [Abstract][Full Text] [Related]
13. Genetics of Cushing's disease.
Albani A; Theodoropoulou M; Reincke M
Clin Endocrinol (Oxf); 2018 Jan; 88(1):3-12. PubMed ID: 28850717
[TBL] [Abstract][Full Text] [Related]
14. The USP8 mutational status may predict drug susceptibility in corticotroph adenomas of Cushing's disease.
Hayashi K; Inoshita N; Kawaguchi K; Ibrahim Ardisasmita A; Suzuki H; Fukuhara N; Okada M; Nishioka H; Takeuchi Y; Komada M; Takeshita A; Yamada S
Eur J Endocrinol; 2016 Feb; 174(2):213-26. PubMed ID: 26578638
[TBL] [Abstract][Full Text] [Related]
15. Responsiveness to DDAVP in Cushing's disease is associated with USP8 mutations through enhancing AVPR1B promoter activity.
Shichi H; Fukuoka H; Kanzawa M; Yamamoto M; Yamamoto N; Suzuki M; Urai S; Matsumoto R; Kanie K; Fujita Y; Bando H; Iguchi G; Inoshita N; Yamada S; Takahashi Y; Ogawa W
Pituitary; 2022 Jun; 25(3):496-507. PubMed ID: 35451730
[TBL] [Abstract][Full Text] [Related]
16. USP8 Mutations and Cell Cycle Regulation in Corticotroph Adenomas.
Martins CS; Camargo RC; Coeli-Lacchini FB; Saggioro FP; Moreira AC; de Castro M
Horm Metab Res; 2020 Feb; 52(2):117-123. PubMed ID: 32053843
[TBL] [Abstract][Full Text] [Related]
17. The New Molecular Landscape of Cushing's Disease.
Sbiera S; Deutschbein T; Weigand I; Reincke M; Fassnacht M; Allolio B
Trends Endocrinol Metab; 2015 Oct; 26(10):573-583. PubMed ID: 26412158
[TBL] [Abstract][Full Text] [Related]
18. Targeting the ERK pathway for the treatment of Cushing's disease.
Zhang D; Bergsneider M; Wang MB; Heaney AP
Oncotarget; 2016 Oct; 7(43):69149-69158. PubMed ID: 27708250
[TBL] [Abstract][Full Text] [Related]
19. Paediatric Cushing's disease - a literature review of epidemiology, pathogenesis, clinical symptoms, and diagnostics.
Pasternak-Pietrzak K; Moszczyńska E; Jurkiewicz E; Szalecki M
Endokrynol Pol; 2020; 71(1):87-95. PubMed ID: 32129467
[TBL] [Abstract][Full Text] [Related]
20. Feasibility analysis of ACTH adenoma model in USP8-/- mice.
Li J; Wu N; Zhu D; Zhu Y
Endokrynol Pol; 2023; 74(2):181-189. PubMed ID: 36916541
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
